ELI LILLY & CO

Explore how Eli Lilly’s obesity drug forecast and Atai Beckley acquisition could reshape its portfolio, investor sentiment, and earnings prospects.

Retatrutide’s Phase‑3 win proves it’s a top‑tier weight‑loss & diabetes drug, promising a 2027 BLA and a new growth engine for Eli Lilly investors.

Explore how Eli Lilly’s $3.8 B purchase of AtaiBeckley marks a bold entry into psychedelic medicine, reshaping its portfolio and the neuro‑psychiatric market.

Explore how Eli Lilly’s GLP‑1 drugs are driving multi‑billion growth, defensive resilience, and analyst confidence in today’s volatile pharma market.

Explore Eli Lilly’s July 2026 market update: analyst upgrades, new Alzheimer’s biomarker data, Canadian eczema approval, and European pricing risks.

Explore Eli Lilly’s 2026 highlights: new Alzheimer’s tests, weight‑loss surge, Canadian eczema approval, and EU price‑pressure challenges.

Discover how Eli Lilly’s GLP‑1 drugs drove the company past $1 trillion, sparking new Asia expansion and a bullish future for pharma.

Discover how Eli Lilly’s partnership with DKSH will expand its Hong Kong and Macau reach, boost patient access, and drive growth in a booming Greater China market.

Explore how Eli Lilly’s Medicare GLP‑1 coverage boost and Chinese partnership shift impact its stock and global strategy.

Explore Eli Lilly’s record‑high surge—driven by oncology breakthroughs, GLP‑1 weight‑loss momentum, and strategic biotech partnerships—and the risks that could reshape its future.